IP Library › Granted Patent US 12,227,571
Granted Patent B2
US 12,227,571 · App. 16/770,441 · Granted Feb 18, 2025

Continuous manufacturing process for bispecific antibody products

Inventors: Chetan Goudar (Newbury Park, CA); Rohini Deshpande (Camarillo, CA); Natalia Gomez (Playa Vista, CA); Hedieh Barkhordarian (Newbury Park, CA); Yan Wang (Thousand Oaks, CA)
Assignee: AMGEN INC.
C07K16/2809C07K16/2863C07K16/2878C07K16/3069C12M29/10C12N5/0018B01F2101/44B01J2219/00725B01J2219/2446B01J2219/2466C07K2317/14C07K2317/31C07K2317/565C07K2317/94C12M3/00C12M21/00C12N2521/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,227,571
App. No.
16/770,441
Granted
Feb 18, 2025
Kind
B2
Abstract

The present invention provides a continuous upstream manufacturing process for the production of bispecific antibody products, which comprise at least two binding domains. The process comprises at least the steps of (i) providing in a perfusion bioreactor at least one mammalian cell culture, which is capable of expressing the bispecific antibody product, (ii) growing the mammalian cell culture at a first perfusion rate until a set point viable cell density is reached, and (iii) maintaining perfusion culture at a second perfusion rate, wherein the bispecific antibody product concentration in the bioreactor is kept below a threshold value. The bispecific antibody product is then subject to subsequent downstream processing. Moreover, the invention provides a bispecific antibody product produced by the continuous upstream manufacturing process.

Claims (47)

1. A continuous upstream manufacturing process for the production of a bispecific antibody product comprising at least a first and a second binding domain, wherein the first binding domain binds to a different target than the second binding domain, wherein the bispecific antibody product is a non-full length bispecific antibody construct, and wherein the bispecific antibody product is a bispecific T-cell engager antibody construct, the process comprising the steps, in order, of:

(i) providing a liquid cell culture medium comprising at least one mammalian cell culture in a perfusion bioreactor, wherein the mammalian cell culture is expressing the bispecific antibody product, and wherein the cells have a concentration of at least 0.4×10 6 cells/mL at inoculation in the perfusion bioreactor,

(ii) growing the mammalian cell culture by applying a perfusion rate (D) to exchange the liquid cell culture medium in a continuous manner, without removing the cells from bioreactor, wherein the perfusion rate initially corresponds to at least 0.4 vessel volume per day (vvd) and is then increased continuously, gradually or incrementally to at least 2 vvd reaching a biomass set-point, wherein the biomass set-point equals to a viable cell density (VCD) of at least 35×10 6 cells/mL,

(iii) maintaining perfusion culture by applying the perfusion rate (D) to continuously or incrementally exchange the liquid cell culture medium, wherein the perfusion rate in step (iii) is in the range from 2 to 6.4 vvd, and wherein the perfusion rate (D) is a cell-specific perfusion rate (CSPR) in the range of 0.01 to 0.15 nL per cell per day (nL/cell/day), and

(iv) bleeding extra cells from the bioreactor to maintain the biomass set-point, wherein the bispecific antibody product concentration in the bioreactor is kept below 0.3 g/L by continuously harvesting the bispecific antibody product from the liquid cell culture medium throughout steps (ii) to (iv).

2. The process according to claim 1 , wherein in step (i) the cells have a concentration of at least 1×10 6 cells/mL at inoculation in the bioreactor.

3. The process according to claim 1 , wherein in step (ii) the biomass set-point equals to a VCD of at least 71×10 6 cells/mL.

4. The process according to claim 1 , wherein in step (ii) the growing of the cell culture takes place for at least 4 days.

5. The process according to claim 1 , wherein in step (ii) the initial or increased perfusion rate (D) is in the range from 0.4 to 7 vvd.

6. The process according to claim 1 , wherein in step (iii) the perfusion rate (D) is 2.01 vvd.

7. The process according to claim 1 , wherein in step (iii) the perfusion rate (D) is a cell-specific perfusion rate (CSPR) in the range of 0.015 to 0.035 nL/cell/day or in the range of 0.051 to 0.1 nL/cell/day.

8. The process according to claim 1 , wherein in step (iv) the bispecific antibody product concentration is kept below 0.12 g/L.

9. The process according to claim 1 , wherein the residence time of the bispecific antibody product in the bioreactor before harvest in step (iv) is at most 2 days.

10. The process according to claim 1 , wherein the percentile monomer content of the isolated bispecific antibody is at least 80%.

11. The process according to claim 1 , wherein the first and/or second binding domain binds to a target and/or an effector cell, and wherein the first and the second binding domain of the bispecific antibody construct each comprise two VH and VL domains.

12. The process according to claim 1 , wherein the bispecific antibody construct comprises a half-life extending third domain comprising a hinge-CH2-CH3-linker-hinge-CH2-CH3 in an amino to carboxyl order.

13. The process according to claim 1 , wherein the first binding domain of the bispecific antibody product binds to at least one target cell surface antigen selected from the group consisting of CD19, CD33, EGFRvIII, MSLN, CDH19, FLT3, DLL3, CDH3, BCMA and PSMA.

14. The process according to claim 1 , wherein the second binding domain of the bispecific antibody product binds to CD3.

15. The process according to claim 1 , wherein the first binding domain comprises a VH region comprising CDR-H1, CDR-H2 and CDR-H3 and a VL region comprising CDR-L1, CDR-L2 and CDR-L3 selected from the group consisting of:

(a) CDR-H1 as depicted in SEQ ID NO: 1, CDR-H2 as depicted in SEQ ID NO: 2, CDR-H3 as depicted in SEQ ID NO: 3, CDR-L1 as depicted in SEQ ID NO: 4, CDR-L2 as depicted in SEQ ID NO: 5 and CDR-L3 as depicted in SEQ ID NO: 6,

(b) CDR-H1 as depicted in SEQ ID NO: 29, CDR-H2 as depicted in SEQ ID NO: 30, CDR-H3 as depicted in SEQ ID NO: 31, CDR-L1 as depicted in SEQ ID NO: 34, CDR-L2 as depicted in SEQ ID NO: 35 and CDR-L3 as depicted in SEQ ID NO: 36,

(c) CDR-H1 as depicted in SEQ ID NO: 42, CDR-H2 as depicted in SEQ ID NO: 43, CDR-H3 as depicted in SEQ ID NO: 44, CDR-L1 as depicted in SEQ ID NO: 45, CDR-L2 as depicted in SEQ ID NO: 46 and CDR-L3 as depicted in SEQ ID NO: 47,

(d) CDR-H1 as depicted in SEQ ID NO: 53, CDR-H2 as depicted in SEQ ID NO: 54, CDR-H3 as depicted in SEQ ID NO: 55, CDR-L1 as depicted in SEQ ID NO: 56, CDR-L2 as depicted in SEQ ID NO: 57 and CDR-L3 as depicted in SEQ ID NO: 58,

(e) CDR-H1 as depicted in SEQ ID NO: 65, CDR-H2 as depicted in SEQ ID NO: 66, CDR-H3 as depicted in SEQ ID NO: 67, CDR-L1 as depicted in SEQ ID NO: 68, CDR-L2 as depicted in SEQ ID NO: 69 and CDR-L3 as depicted in SEQ ID NO: 70,

(f) CDR-H1 as depicted in SEQ ID NO: 83, CDR-H2 as depicted in SEQ ID NO: 84, CDR-H3 as depicted in SEQ ID NO: 85, CDR-L1 as depicted in SEQ ID NO: 86, CDR-L2 as depicted in SEQ ID NO: 87 and CDR-L3 as depicted in SEQ ID NO: 88,

(g) CDR-H1 as depicted in SEQ ID NO: 94, CDR-H2 as depicted in SEQ ID NO: 95, CDR-H3 as depicted in SEQ ID NO: 96, CDR-L1 as depicted in SEQ ID NO: 97, CDR-L2 as depicted in SEQ ID NO: 98 and CDR-L3 as depicted in SEQ ID NO: 99,

(h) CDR-H1 as depicted in SEQ ID NO: 105, CDR-H2 as depicted in SEQ ID NO: 106, CDR-H3 as depicted in SEQ ID NO: 107, CDR-L1 as depicted in SEQ ID NO: 109, CDR-L2 as depicted in SEQ ID NO: 110 and CDR-L3 as depicted in SEQ ID NO: 111,

(i) CDR-H1 as depicted in SEQ ID NO: 115, CDR-H2 as depicted in SEQ ID NO: 116, CDR-H3 as depicted in SEQ ID NO: 117, CDR-L1 as depicted in SEQ ID NO: 118, CDR-L2 as depicted in SEQ ID NO: 119 and CDR-L3 as depicted in SEQ ID NO: 120,

(j) CDR-H1 as depicted in SEQ ID NO: 126, CDR-H2 as depicted in SEQ ID NO: 127, CDR-H3 as depicted in SEQ ID NO: 128, CDR-L1 as depicted in SEQ ID NO: 129, CDR-L2 as depicted in SEQ ID NO: 130 and CDR-L3 as depicted in SEQ ID NO: 131,

(k) CDR-H1 as depicted in SEQ ID NO: 137, CDR-H2 as depicted in SEQ ID NO: 138, CDR-H3 as depicted in SEQ ID NO: 139, CDR-L1 as depicted in SEQ ID NO: 140, CDR-L2 as depicted in SEQ ID NO: 141 and CDR-L3 as depicted in SEQ ID NO: 142,

(l) CDR-H1 as depicted in SEQ ID NO: 152, CDR-H2 as depicted in SEQ ID NO: 153, CDR-H3 as depicted in SEQ ID NO: 154, CDR-L1 as depicted in SEQ ID NO: 155, CDR-L2 as depicted in SEQ ID NO: 156 and CDR-L3 as depicted in SEQ ID NO: 157, and

(m) CDR-H1 as depicted in SEQ ID NO: 167, CDR-H2 as depicted in SEQ ID NO: 168, CDR-H3 as depicted in SEQ ID NO: 169, CDR-L1 as depicted in SEQ ID NO: 170, CDR-L2 as depicted in SEQ ID NO: 171 and CDR-L3 as depicted in SEQ ID NO: 172.

16. The process according to claim 1 , wherein the harvested bispecific antibody product is comprised in harvested cell culture fluid (HCCF).

17. The process according to claim 1 , wherein the HCCF is collected at room temperature in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 24, 36, 48, 72, 96, 120, or 144 hour increments or continuously and passed to downstream steps for further processing the bispecific antibody product.

18. The process according to claim 17 , wherein the downstream steps comprise capture chromatography, viral inactivation, and/or polishing steps.

19. The process according to claim 1 , wherein the perfusion culture is continuously running for at least 7 days by feeding at the defined cell-specific perfusion rate and bleeding extra cells from the bioreactor to maintain the biomass set-point.

20. The process according to claim 1 , wherein the bispecific antibody product is a single chain antibody construct.

21. The process according to claim 1 , wherein the bispecific antibody product comprises in an amino to carboxyl order:

(a) the first domain;

(b) a peptide linker having an amino acid sequence selected from the group consisting of SEQ ID Nos: 187-189;

(c) the second domain;

(d) a peptide linker having an amino acid sequence selected from the group consisting of SEQ ID NO: 187, 188, 189, 195, 196, 197 and 198;

(e) the first polypeptide monomer of a third domain;

(f) a peptide linker having an amino acid sequence selected from the group consisting of SEQ ID Nos: 191, 192, 193 and 194; and

(g) the second polypeptide monomer of the first domain.

22. The process according to claim 1 , wherein the first binding domain of the bispecific antibody product binds to at least one tumor antigen.

23. The process according to claim 1 , wherein the biomass set-point equals to a viable cell density (VCD) of at least 65×10 6 cells/mL.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2021
From: GOUDAR, CHETAN; DESHPANDE, ROHINI; GOMEZ, NATALIA; BARKHORDARIAN, HEDIEH; WANG, YAN
To: AMGEN INC.
Reel/Frame 055548/0846 →
Continuity (2)
Provisional Application 62597250 · Dec 11, 2017
Related Publication 20210163592A1 · Jun 3, 2021
References Cited (281)
US 3691016A · Patel · 1972 [cited by applicant]
US 3773919A · Boswell et al. · 1973 [cited by applicant]
US 3969287A · Jaworek et al. · 1976 [cited by applicant]
US 4179337A · Davis et al. · 1979 [cited by applicant]
US 4195128A · Gribnau et al. · 1980 [cited by applicant]
US 4229537A · Hodgins et al. · 1980 [cited by applicant]
US 4247642A · Hirohara et al. · 1981 [cited by applicant]
US 4301144A · Washita et al. · 1981 [cited by applicant]
US 4330440A · Ayers et al. · 1982 [cited by applicant]
US 4439196A · Higuchi · 1984 [cited by applicant]
US 4447224A · Decant et al. · 1984 [cited by applicant]
US 4447233A · Mayfield · 1984 [cited by applicant]
US 4475196A · La Zor · 1984 [cited by applicant]
US 4485045A · Regen · 1984 [cited by applicant]
US 4486194A · Ferrara · 1984 [cited by applicant]
US 4487603A · Harris · 1984 [cited by applicant]
US 4496689A · Mitra · 1985 [cited by applicant]
US 4544545A · Ryan et al. · 1985 [cited by applicant]
US 4596556A · Morrow et al. · 1986 [cited by applicant]
US 4640835A · Shimizu et al. · 1987 [cited by applicant]
US 4670417A · Iwasaki et al. · 1987 [cited by applicant]
US 4694778A · Learn et al. · 1987 [cited by applicant]
US 4751180A · Cousens et al. · 1988 [cited by applicant]
US 4790824A · Morrow et al. · 1988 [cited by applicant]
US 4791192A · Nakagawa et al. · 1988 [cited by applicant]
US 4816397A · Boss et al. · 1989 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 4935233A · Bell et al. · 1990 [cited by applicant]
US 4941880A · Burns · 1990 [cited by applicant]
US 4946778A · Adner et al. · 1990 [cited by applicant]
US 5013556A · Woodle et al. · 1991 [cited by applicant]
US 5064413A · Mckinnon et al. · 1991 [cited by applicant]
US 5223409A · Ladner et al. · 1993 [cited by applicant]
US 5225539A · Winter · 1993 [cited by applicant]
US 5260203A · Ladner et al. · 1993 [cited by applicant]
US 5292658A · Cormier et al. · 1994 [cited by applicant]
US 5312335A · Mckinnon et al. · 1994 [cited by applicant]
US 5383851A · Mckinnon et al. · 1995 [cited by applicant]
US 5399163A · Peterson et al. · 1995 [cited by applicant]
US 5418155A · Cormier et al. · 1995 [cited by applicant]
US 5476996A · Wilson et al. · 1995 [cited by applicant]
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 5545807A · Surani et al. · 1996 [cited by applicant]
US 5565332A · Hoogenboom et al. · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5591669A · Krimpenfort et al. · 1997 [cited by applicant]
US 5612205A · Kay et al. · 1997 [cited by applicant]
US 5625126A · Onberg et al. · 1997 [cited by applicant]
US 5625825A · Rostoker et al. · 1997 [cited by applicant]
US 5633425A · Lonberg et al. · 1997 [cited by applicant]
US 5643763A · Dunn et al. · 1997 [cited by applicant]
US 5648260A · Winter et al. · 1997 [cited by applicant]
US 5661016A · Lonberg et al. · 1997 [cited by applicant]
US 5683888A · Campbell · 1997 [cited by applicant]
US 5693761A · Queen et al. · 1997 [cited by applicant]
US 5693762A · Queen et al. · 1997 [cited by applicant]
US 5698767A · Wilson et al. · 1997 [cited by applicant]
US 5721367A · Kay et al. · 1998 [cited by applicant]
US 5741668A · Ward et al. · 1998 [cited by applicant]
US 5770429A · Lonberg et al. · 1998 [cited by applicant]
US 5777079A · Tsien et al. · 1998 [cited by applicant]
US 5789215A · Berns et al. · 1998 [cited by applicant]
US 5789650A · Lonberg et al. · 1998 [cited by applicant]
US 5804387A · Cormack et al. · 1998 [cited by applicant]
US 5814318A · Lonberg et al. · 1998 [cited by applicant]
US 5859205A · Adair et al. · 1999 [cited by applicant]
US 5874299A · Lonberg et al. · 1999 [cited by applicant]
US 5874304A · Zolotukhin et al. · 1999 [cited by applicant]
US 5876995A · Bryan · 1999 [cited by applicant]
US 5877397A · Lonberg et al. · 1999 [cited by applicant]
US 5925558A · Tsien et al. · 1999 [cited by applicant]
US 5939598A · Kucherlapati et al. · 1999 [cited by applicant]
US 5958765A · Brams et al. · 1999 [cited by applicant]
US 5981175A · Loring et al. · 1999 [cited by applicant]
US 6023010A · Krimpenfort et al. · 2000 [cited by applicant]
US 6075181A · Kucherlapati et al. · 2000 [cited by applicant]
US 6114598A · Kucherlapati et al. · 2000 [cited by applicant]
US 6150584A · Kucherlapati et al. · 2000 [cited by applicant]
US 6162963A · Kucherlapati et al. · 2000 [cited by applicant]
US 6255458B1 · Lonberg et al. · 2001 [cited by applicant]
US 6300064B1 · Knappik et al. · 2001 [cited by applicant]
US 6407213B1 · Carter et al. · 2002 [cited by applicant]
US 6673986B1 · Kucherlapati et al. · 2004 [cited by applicant]
US 20030070185A1 · Jakobovits et al. · 2003 [cited by applicant]
US 20050076395A1 · Kucherlapati et al. · 2005 [cited by applicant]
US 20140302037A1 · Borges et al. · 2014 [cited by applicant]
US 20140308285A1 · Yan et al. · 2014 [cited by applicant]
US 20170204446A1 · Cattaneo et al. · 2017 [cited by applicant]
US 20200332251A1 · Lin · 2020 [cited by examiner]
EP 0088046A2 · 1983 [cited by applicant]
EP 0133988A2 · 1985 [cited by applicant]
EP 0171496A2 · 1986 [cited by applicant]
EP 0173494A2 · 1986 [cited by applicant]
EP 0183070A2 · 1986 [cited by applicant]
EP 0058481B1 · 1986 [cited by applicant]
EP 0244234A2 · 1987 [cited by applicant]
EP 0143949B1 · 1988 [cited by applicant]
EP 0036676B2 · 1990 [cited by applicant]
EP 0402226A1 · 1990 [cited by applicant]
EP 0463151A1 · 1992 [cited by applicant]
EP 0239400B1 · 1994 [cited by applicant]
EP 0773288A2 · 1997 [cited by applicant]
EP 0546073B1 · 1997 [cited by applicant]
EP 0843961A1 · 1998 [cited by applicant]
GB 2177096A · 1987 [cited by applicant]
JP 3068180B2 · 2000 [cited by applicant]
JP 3068506B2 · 2000 [cited by applicant]
JP 3068507B2 · 2000 [cited by applicant]
WO 198705330A1 · 1987 [cited by applicant]
WO 198801649A1 · 1988 [cited by applicant]
WO 198809344A1 · 1988 [cited by applicant]
WO 199110741A1 · 1991 [cited by applicant]
WO 199203918A1 · 1992 [cited by applicant]
WO 199215673A1 · 1992 [cited by applicant]
WO 199222645A1 · 1992 [cited by applicant]
WO 199222647A1 · 1992 [cited by applicant]
WO 199222670A1 · 1992 [cited by applicant]
WO 199312227A1 · 1993 [cited by applicant]
WO 199315722A1 · 1993 [cited by applicant]
WO 199400569A1 · 1994 [cited by applicant]
WO 199402602A1 · 1994 [cited by applicant]
WO 199425585A1 · 1994 [cited by applicant]
WO 199507463A1 · 1995 [cited by applicant]
WO 199614436A1 · 1996 [cited by applicant]
WO 199633735A1 · 1996 [cited by applicant]
WO 199634096A1 · 1996 [cited by applicant]
WO 199713852A1 · 1997 [cited by applicant]
WO 199738731A1 · 1997 [cited by applicant]
WO 199814605A1 · 1998 [cited by applicant]
WO 199824884A1 · 1998 [cited by applicant]
WO 199824893A2 · 1998 [cited by applicant]
WO 199826277A2 · 1998 [cited by applicant]
WO 199852976A1 · 1998 [cited by applicant]
WO 199949019A2 · 1999 [cited by applicant]
WO 199954440A1 · 1999 [cited by applicant]
WO 200006605A2 · 2000 [cited by applicant]
WO 200034317A2 · 2000 [cited by applicant]
WO 200076310A1 · 2000 [cited by applicant]
WO 200347336A2 · 2003 [cited by applicant]
WO 2005040220A1 · 2005 [cited by applicant]
WO 2006138181A2 · 2006 [cited by applicant]
WO 2007042261A2 · 2007 [cited by applicant]
WO 2008119567A2 · 2008 [cited by applicant]
WO 2010037838A2 · 2010 [cited by applicant]
WO 2010052014A1 · 2010 [cited by applicant]
WO 2010060719A1 · 2010 [cited by applicant]
WO 2013026833A1 · 2013 [cited by applicant]
WO 2013026837A1 · 2013 [cited by applicant]
WO 2014144722A2 · 2014 [cited by applicant]
WO 2014151910A1 · 2014 [cited by applicant]
WO 2015048272A1 · 2015 [cited by applicant]
WO 2017072201A2 · 2017 [cited by applicant]
WO 2017134140A1 · 2017 [cited by applicant]
Altschul et al., Basic local alignment search tool, J. Mol. Biol., 215(3):403-410 (1990). [cited by applicant]
Altschul et al., Gapped BLAST and PSI-BLAST: a new generation of protein database search programs, Nucl. Acids Res., 25(17):3389-3402 (1993). [cited by applicant]
Altschul et al., Gapped blast and PSI-BLAST: a new generation of protein database search programs, Nucleic Acids Res., 25(17):3389-3402 (1997). [cited by applicant]
Altschul et al., Local alignment statistics, Meth. Enz., 266:460-480 (1996). [cited by applicant]
Aplin et al., Preparation, properties, and applications of carbohydrate conjugates of proteins and lipids, CRC Crit. Rev. Biochem., 10(4):259-306 (1981). [cited by applicant]
Arakawa et al., Protein-solvent interactions in pharmaceutical formulations, Pharm. Res., 8(3):285-91 (1991). [cited by applicant]
Artsaenko et al., Expression of a single-chain Fv antibody against abscisic acid creates a willy phenotype in transgenic tobacco, Plant J., 8(5):745-750 (1995). [cited by applicant]
Bird et al., Single-chain antigen-binding proteins, Science, 242(4877):423-442 (1988). [cited by applicant]
Bratt et al., Therapeutic IgG-Like Bispecific Antibodies: Modular Versatility and Manufacturing Challenges, Part 2, BioProcess International, pp. 1-14 (2018). [cited by applicant]
Briihl et al., Depletion of CCR5-expressing cells with bispecific antibodies and chemokine toxins: a new strategy in the treatment of chronic inflammatory diseases and HIV, Immunol., 166(4):2420-2426 (2001). [cited by applicant]
Carter et al., High level [cited by applicant]
Carvalho et al., Production Processes for Monoclonal Antibodies, In: Ferm. Proc., XP055562271 (2017). [cited by applicant]
Chalfie et al., Green fluorescent protein as a marker for gene expression, Science, 263:802-805 (1994). [cited by applicant]
Cheadle et al., Cloning and expression of the variable regions of mouse myeloma protein MOPC315 in [cited by applicant]
Cheson et al., Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group, J. Clin. Oncol., 7(4):1244 (1999). [cited by applicant]
Chi et al., Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation, Phann. Res., 20(9):1325-1336 (2003). [cited by applicant]
Chothia et al., Canonical structures for the hypervariable regions of immunoglobulins, J. Mol. Biol., 196(4):901-917 (1987). [cited by applicant]
Chothia et al., Conformations of immunoglobulin hypervariable regions, Nature, 342:877-83 (1989). [cited by applicant]
Christopher, Therapeutic protein aggregation: mechanisms, design, and control, Trends Biotechnol., 32(7):372-80 (2014). [cited by applicant]
Clackson et al., Making antibody fragments using phage display libraries, Nature, 352:624-628 (1991). [cited by applicant]
Cole et al., Monoclonal antibodies and cancer therapy, Alan R. Liss, Inc., 77-96 (1985). [cited by applicant]
Cook et al., The human immunoglobulin VH repertoire, Immunol. Today, 16(5):237-242 (1995). [cited by applicant]
Creighton, Proteins: Structure and molecular properties, W. H Freeman & Co., San Francisco, 79-86 (1983). [cited by applicant]
Cunningham et al., High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis, Science, 244:1081-1085 (1989). [cited by applicant]
Current Methods in Sequence Comparison and Analysis, Macromolecule Sequencing and Synthesis, Selected Methods and Applications, 127-149 (1988). [cited by applicant]
Dall'Acqua et al., Contribution of domain interface residues to the stability of antibody CH3 domain homodimers, Biochem., 37(26):9266-9273 (1998). [cited by applicant]
Devereux et al., A comprehensive set of sequence analysis programs for the VAX, Nucl. Acid. Res., 12:387-395 (1984). [cited by applicant]
Duskin et al., Relationship of the structure and biological activity of the natural homologues of tunicamycin, J. Biol. Chem., 257(6):3105-9(1982). [cited by applicant]
Edge et al., Deglycosylation of glycoproteins by trifluoromethanesulfonic acid, Anal. Biochem., 118(1):131-7 (1981). [cited by applicant]
Eppstein et al., Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor, Proc. Natl. Acad. Sci. USA., 82(11):3688-3692 (1985). [cited by applicant]
Fan et al., Bispecific antibodies and their applications, Journal of Hematology & Oncology, 8:130 (2015). [cited by applicant]
Feng et al., Progressive sequence alignment as a prerequisite to correct phylogenetic trees, J. Mol. Evol., 25(4):351-360 (1987). [cited by applicant]
Gabizon et al., Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times, J. National Cancer Inst., 81(19):1484-8 (1989). [cited by applicant]
Graham et al., Characteristics of a human cell line transformed by DNA from human adenovirus type 5, J. Gen. Virol., 36(1):59-74 (1977). [cited by applicant]
Green et al., Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs, Nat. Gene., 7(1):13-21 (1994). [cited by applicant]
Green et al., Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes, J. Exp. Med., 188:483-495 (1998). [cited by applicant]
Hakimuddin et al., A chemical method for the deglycosylation of proteins, Arch. Biochem. Biophys., 259(1):52-57 (1987). [cited by applicant]
Hawkins et al., Selection of phage antibodies by binding affinity. Mimicking affinity maturation, J. Mol. Biol., 226(3):889-896 (1992). [cited by applicant]
Hein et al., Engineering green fluorescent protein for improved brightness, longer wavelengths and fluorescence resonance energy transfer, Curr. Biol., 6(2):178-182 (1996). [cited by applicant]
Hiatt et al., Production of antibodies in transgenic plants, Nature, 342:76-78 (1989). [cited by applicant]
Higgins et al., Fast and sensitive multiple sequence alignments on a microcomputer, Comput. Appl. Biosci., 5(2):151-3 (1989). [cited by applicant]
Hollinger et al., “Diabodies”: small bivalent and bispecific antibody fragments, Proc. Natl. Acad. Sci. USA., 90(14):6444-8 (1993). [cited by applicant]
Huston et al., Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in [cited by applicant]
Hwang et al., Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study, Proc. Natl. Acad. Sci. USA., 77(7):4030-4 (1980). [cited by applicant]
Hwang et al., Immunogenicity of engineered antibodies, Methods, 36(1):3-10 (2005). [cited by applicant]
Ichiki et al., Regulation of the expression of human C epsilon germline transcript. Identification of a novel IL-4 responsive element, J. Immunol., 150(12):5408-5417 (1993). [cited by applicant]
International Application No. PCT/US2018/064901, International Search Report and Written Opinion, mailed on Mar. 21, 2019. [cited by applicant]
International Application No. PCT/US2018/064901, International Preliminary Report on Patentability, mailed Jun. 25, 2020. [cited by applicant]
Jones et al., Replacing the complementarity-determining regions in a human antibody with those from a mouse, Nature, 321:522-525 (1986). [cited by applicant]
Karin et al., Applications and statistics for multiple high-scoring segments in molecular sequences, Proc. Natl. Acad. Sci. USA., 90(12):5873-5787 (1993). [cited by applicant]
Kendrick et al., Physical stabilization of proteins in aqueous solution, Pharmaceutical Biotechnology, 13:61-84 (2002). [cited by applicant]
Kipriyanov et al., Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics, J. Mol. Biol., 293(1):41-56 (1999). [cited by applicant]
Koehler et al., Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, 256:495-7 (1975). [cited by applicant]
Kozbor et al., The production of monoclonal antibodies from human lymphocytes, Immunology Today, 4(3):72-9 (1983). [cited by applicant]
Kufer et al., A revival of bispecific antibodies, Trends in Biotechnol., 22(5):238-244 (2004). [cited by applicant]
Kufer et al., Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer, Cancer Immunol. Immunother., 45:193-197 (1997). [cited by applicant]
Lachmann, Bispecific antibody: a tool for diagnosis and treatment of disease, Clin. Exp. Immunol., 79(3):315-321 (1990). [cited by applicant]
Langer et al., Biocompatibility of polymeric delivery systems for macromolecules, J. Biomed. Mater. Res., 15(2):267-277 (1981). [cited by applicant]
Langer, Controlled release of macromolecules, Chem. Tech., 12(2):98-105 (1982). [cited by applicant]
Leader et al., Protein therapeutics: a summary and pharmacological classification, Nat. Rev. Drug Discovery, 7(1):21-39 (2008). [cited by applicant]
Loffler et al., A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes, Blood, 95(6):2098-2103 (2000). [cited by applicant]
Lowman et al., Selecting high-affinity binding proteins by monovalent phage display, Biochemistry, 30(45):10832-10837 (1991). [cited by applicant]
Maccallum et al., Antibody-antigen interactions: contact analysis and binding site topography, J. Mol. Biol., 262(5):732-45 (1996). [cited by applicant]
Mack et al., A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity, PNAS, 92(15):7021-7025 (1995). [cited by applicant]
Mack et al., Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity, J. Immunol., 158(8):3965-3970 (1997). [cited by applicant]
Malmborg et al., BIAcore as a tool in antibody engineering, J. Immunol. Methods, 183(1):7-13 (1995). [cited by applicant]
Marks et al., By-passing immunization. Human antibodies from V-gene libraries displayed on phage, J. Mol. Biol., 222(3):581-597 (1991). [cited by applicant]
Martin et al., Irreversible coupling of immunoglobulin fragments to preformed vesicles. an improved method for liposome targeting, J. Biol. Chem., 257(1):286-288 (1982). [cited by applicant]
Martin et al., Structural families in loops of homologous proteins: automatic classification, modelling and application to antibodies, J. Mol. Biol., 263(5):800-15 (1996). [cited by applicant]
Mather et al., Culture of testicular cells in hormone-supplemented serum-free medium, Annals N. Y. Acad. Sci., 383:44-68 (1982). [cited by applicant]
Mather, Establishment and characterization of two distinct mouse testicular epithelial cell lines, Biol. Reprod., 23(1):243-251 (1980). [cited by applicant]
Mendez et al., Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice, Nat. Gen., 15(2):146-156 (1997). [cited by applicant]
Morrison et al., Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains, Proc. Natl. Acad. Sci. USA., 81(21):6851-6855 (1984). [cited by applicant]
Morrison et al., Combinatorial alanine-scanning, Cur. Opin. Chem. Biol., 5(3):302-307 (2001). [cited by applicant]
Morrison, Transfectomas provide novel chimeric antibodies, Science, 229:1202-1207 (1985). [cited by applicant]
Needleman et al., A general method applicable to the search for similarities in the amino acid sequence of two proteins, J. Mol. Biol., 48(3):443-53 (1970). [cited by applicant]
Nolan et al., Fluorescence-activated cell analysis and sorting of viable mammalian cells based on beta-D-galactosidase activity after transduction of [cited by applicant]
Oi et al., Chimeric antibodies, BioTechniques, 4(3):214-221 (1986). [cited by applicant]
Olsson et al., Human—human monoclonal antibody-producing hybridomas: technical aspects, Meth. Enzymol., 92:3-16 (1982). [cited by applicant]
Owen et al., Synthesis of a functional anti-phytochrome single-chain Fv protein in transgenic tobacco, BioTechnology, 10(7):790-794 (1992). [cited by applicant]
Padlan, Anatomy of the antibody molecule, Mol. Immunol., 31(3):169-217 (1993). [cited by applicant]
Pearson et al., Improved tools for biological sequence comparison, Proc. Nat. Acad. Sci. USA., 85(8):2444-8 (1988). [cited by applicant]
Pecker et al., Expression of single-chain antibody fragments (scFv) specific for beet necrotic yellow vein virus coat protein or 25 kDa protein in [cited by applicant]
Presta, Current opinion in structural biology, Curr. Op. Struct. Biol., 2(4):593-596 (1992). [cited by applicant]
Raag et al., Single-chain Fvs, FASEB, 9(1):73-80 (1995). [cited by applicant]
Randolph et al., Surfactant-protein interactions, Pharm. Biotechnol., 13:159-75 (2002). [cited by applicant]
Reichmann et al., Reshaping human antibodies for therapy, Nature, 332:323-329 (1988). [cited by applicant]
Schier et al., Efficient in vitro affinity maturation of phage antibodies using BIAcore guided selections, Human Antibodies Hybridomas, 7(3):97-105 (1996). [cited by applicant]
Schlereth et al., T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct, Cancer Immunol. Immunother., 55(5):503-14 (2006). [cited by applicant]
Sherman et al., Continuous Cell Culture Operation at 2,000-L Scale, Bioprocess International, 14(10):22-28 (2016). [cited by applicant]
Shukla et al., Evolving trends in mAb production processes, Bioeng. Transl. Med., 2(1):58-69 (2017). [cited by applicant]
Sidman et al., Controlled release of macromolecules and pharmaceuticals from synthetic polypeptides based on glutamic acid, Biopolymers, 2(1):547-556 (1983). [cited by applicant]
Single chain antibodies are discussed in detail by pluckthun in The pharmacology of monoclonal antibodies, Rosenburg and Moore eds. Springer-Verlag, New York, 113:269-315 (1994). [cited by applicant]
Skerra et al., Assembly of a functional immunoglobulin Fv fragment in [cited by applicant]
Smith et al., Comparison of biosequences, Adv. Appl. Math., 2(4):482-489 (1981). [cited by applicant]
Smith, Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface, Science, 228:1315-1317 (1985). [cited by applicant]
Stauber et al., Development and applications of enhanced green fluorescent protein mutants, Biotechniques, 24(3):462-471 (1998). [cited by applicant]
Takeda et al., Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences, Nature, 314:452-54 (1985). [cited by applicant]
Teng et al., Construction and testing of mouse—human heteromyelomas for human monoclonal antibody production, Proc. Natl. Acad. Sci. USA., 80(23):7308-7312 (1983). [cited by applicant]
Thotakura et al., Enzymatic deglycosylation of glycoproteins, Meth. Enzymol., 138:350-9 (1987). [cited by applicant]
Tomlinson et al., The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops, J. Mol. Biol., 227(3):776-798 (1992). [cited by applicant]
Tomlinson et al., The structural repertoire of the human V kappa domain, EMBO J., 14(18):4628-4638 (1995). [cited by applicant]
Tsuneo et al., Fed-batch techniques in microbial processes, Bioprocess Parameter Control, 30:147-194 (2005). [cited by applicant]
U.S. Patent Application filed Apr. 27, 1995, by Kucherlapati et al., U.S. Appl. No. 08/430,938. [cited by applicant]
U.S. Patent Application filed Apr. 28, 1994, by Kucherlapati et al., 08/234, 145. [cited by applicant]
U.S. Patent Application filed Aug. 27, 1993, by Kucherlapati et al., U.S. Appl. No. 08/112,848. [cited by applicant]
U.S. Patent Application filed Aug. 31, 1990, by Lonberg et al., U.S. Appl. No. 07/575,962. [cited by applicant]
U.S. Patent Application filed Dec. 3, 1996, by Jakobovits et al., U.S. Appl. No. 08/759,620. [cited by applicant]
U.S. Patent Application filed Jan. 12, 1990, by Kucherpatali et al., U.S. Appl. No. 07/466,008. [cited by applicant]
U.S. Patent Application filed Jul. 24, 1992, by Kucherlapati et al., U.S. Appl. No. 07/919,297. [cited by applicant]
U.S. Patent Application filed Jun. 5, 1995, by Kucherlapati et al., U.S. Appl. No. 07/574,748. [cited by applicant]
U.S. Patent Application filed Jun. 5, 1995, by Kucherlapati et al., U.S. Appl. No. 08/463,191. [cited by applicant]
U.S. Patent Application filed Jun. 23, 1992, by Lonberg et al., U.S. Appl. No. 07/904,068. [cited by applicant]
U.S. Patent Application filed Mar. 9, 1994, by Lonberg et al., U.S. Appl. No. 08/209,741. [cited by applicant]
U.S. Patent Application filed Nov. 8, 1990, by Kucherlapati et al., U.S. Appl. No. 07/610,515. [cited by applicant]
U.S. Appl. No. 08/155,301. [cited by applicant]
U.S. Appl. No. 08/161,739. [cited by applicant]
U.S. Appl. No. 08/165,699. [cited by applicant]
U.S. Appl. No. 08/376,279. [cited by applicant]
U.S. Appl. No. 08/462,837. [cited by applicant]
U.S. Appl. No. 08/464,584. [cited by applicant]
U.S. Appl. No. 08/486,853. [cited by applicant]
U.S. Appl. No. 08/486,859. [cited by applicant]
Urlaub et al., Isolation of chinese hamster cell mutants deficient in dihydrofolate reductase activity, Proc. Natl. Acad. Sci. USA., 77(7):4216-20 (1980). [cited by applicant]
Wang, Instability, stabilization, and formulation of liquid protein pharmaceuticals, Int. J. Phann., 185(2):129-88 (1999). [cited by applicant]
Ward et al., Binding activities of a repertoire of single immunoglobulin variable domains secreted from [cited by applicant]
Yang et al., Bispecific antibodies as a development platform for new concepts and treatment strategies, Int. J. Mol. Sciences, 18(1):48 (2016). [cited by applicant]
Scanlan et al., “Challenges and Strategies for the Downstream Processing of BiSpecific Antibodies (BsAbs),” ADC Review/Journal of Antibody-drug Conjugates (2014). [cited by applicant]
Cited By (1)
US 12,529,024